Human islet allotransplantation with Basiliximab in type I diabetic patients with end-stage renal failure.
Oberholzer
J
J
Division of Surgical Research, Clinic of Digestive and Transplant Surgery, Department of Surgery, University Hospital of Geneva, Geneva, Switzerland. celtrans@cmu.unige.ch
Toso
C
C
Triponez
F
F
Ris
F
F
Bucher
P
P
Demirag
A
A
Lou
J
J
Majno
P
P
Buehler
L
L
Philippe
J
J
Morel
P
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D016022:Case-Control Studies; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D003928:Diabetic Nephropathies / Q000601:surgery*; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000378:metabolism; D006085:Graft Survival / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016381:Islets of Langerhans Transplantation / Q000276:immunology / Q000502:physiology*; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D011993:Recombinant Fusion Proteins; D012086:Reoperation; D012189:Retrospective Studies; D013997:Time Factors; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D000077552:Basiliximab; D001786:Blood Glucose; D002096:C-Peptide; D006442:Glycated Hemoglobin; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins